12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ATS907: Phase IIa started

Altheos began a 2-stage, single-blind, dose-ranging, U.S. Phase IIa trial of once- or twice-daily ATS907 eye drops for up to 28 days in about 210 patients with primary open-angle glaucoma and/or ocular hypertension. The first part will...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >